The biotherapeutic landscape has shifted. While monoclonal antibodies remain a cornerstone of the pipeline, antibody-drug conjugates (ADCs) and bispecific antibodies are now also playing an increasingly important role in development portfolios, thereby adding complexity to analytical teams.

Reliable assay performance depends on more than just good science. Reproducibility across runs, operators and laboratories — combined with the throughput demands of modern biotherapeutic development — puts pressure on workflows where manual steps are a persistent source of variability.

This webcast looks at how the Gyrolab^® automated immunoassay platform from Gyros Protein Technologies helps to address these challenges in practice. We will discuss what automation means for reproducibility and consistency, how it reduces hands-on time without compromising data quality and how it supports higher throughput when development timelines are tight. After providing an overview of the Gyrolab platform, we will present case studies from biotherapeutic analytical development workflows focusing on titer and process impurity testing. These case studies will demonstrate where automation has produced measurable improvements in assay consistency and run efficiency.  

Key Takeaways:

• The Gyrolab platform eliminates manual steps that introduce inconsistency across runs, operators, and laboratories, improving assay reproducibility in biotherapeutic development.
  
  
• Automated immunoassays reduce hands-on time while maintaining data integrity, enabling teams to meet tight development timelines for mAbs, ADCs, and bispecifics.
  
  
• Case studies demonstrate measurable improvements in assay consistency and efficiency for titer quantification and process impurity testing workflows.